KR20220125210A - 다제 안구 제제 및 치료 방법 - Google Patents
다제 안구 제제 및 치료 방법 Download PDFInfo
- Publication number
- KR20220125210A KR20220125210A KR1020227004552A KR20227004552A KR20220125210A KR 20220125210 A KR20220125210 A KR 20220125210A KR 1020227004552 A KR1020227004552 A KR 1020227004552A KR 20227004552 A KR20227004552 A KR 20227004552A KR 20220125210 A KR20220125210 A KR 20220125210A
- Authority
- KR
- South Korea
- Prior art keywords
- copper
- composition
- ophthalmic
- therapeutic agent
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962873121P | 2019-07-11 | 2019-07-11 | |
| US62/873,121 | 2019-07-11 | ||
| PCT/US2020/041837 WO2021007578A1 (en) | 2019-07-11 | 2020-07-13 | Multi-agent ocular formulations and treatment methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220125210A true KR20220125210A (ko) | 2022-09-14 |
Family
ID=74115334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227004552A Pending KR20220125210A (ko) | 2019-07-11 | 2020-07-13 | 다제 안구 제제 및 치료 방법 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220288114A1 (https=) |
| EP (1) | EP3996644A4 (https=) |
| JP (1) | JP2022541152A (https=) |
| KR (1) | KR20220125210A (https=) |
| CN (1) | CN114364355A (https=) |
| AU (2) | AU2020311441B2 (https=) |
| CA (1) | CA3146848A1 (https=) |
| WO (1) | WO2021007578A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019205774B2 (en) * | 2018-01-05 | 2025-01-02 | University Of Utah Research Foundation | Treatment of myopic progression |
| TW202245810A (zh) * | 2021-02-01 | 2022-12-01 | 美商艾維娜傳送系統公司 | 散光之治療 |
| CN114225016B (zh) * | 2021-12-02 | 2024-07-09 | 北京大学第一医院 | 一种用于抑制近视及圆锥角膜进展的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04502012A (ja) * | 1989-09-27 | 1992-04-09 | モスコフスキ ナウチノ―イススレドバテルスキ インスティテュト グラツィニフ ボレツネイ イメニ ゲルムゴルツァ | 進行性近視の治療用組成物 |
| AU7488898A (en) * | 1997-05-16 | 1998-12-08 | Corrective Vision, Inc. | Improved contact lens |
| EP1397132A4 (en) * | 2001-05-25 | 2006-12-13 | Valley Forge Pharmaceuticals I | OPHTHALMIC PIRENZEPINE GEL |
| US20060134226A1 (en) * | 2004-11-16 | 2006-06-22 | Todd Leonard | Compositions useful to treat ocular neovascular diseases and macular degeneration |
| WO2012161655A1 (en) * | 2011-05-23 | 2012-11-29 | Singapore Health Services Pte Ltd | Composition and/or method for reducing and/or preventing myopia progression comprising atropine |
| US9421199B2 (en) * | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| US10010502B2 (en) * | 2015-05-19 | 2018-07-03 | Amorphex Therapeutics Llc | Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation |
| EP3426262B1 (en) * | 2016-03-08 | 2023-08-23 | University of Utah Research Foundation | Cross-linking agents and associated methods |
| US20200345542A1 (en) * | 2017-11-21 | 2020-11-05 | Sydnexis, Inc. | Ophthalmic composition and delivery device thereof |
| AU2019205774B2 (en) * | 2018-01-05 | 2025-01-02 | University Of Utah Research Foundation | Treatment of myopic progression |
-
2020
- 2020-07-13 CN CN202080063471.0A patent/CN114364355A/zh active Pending
- 2020-07-13 EP EP20836819.1A patent/EP3996644A4/en active Pending
- 2020-07-13 WO PCT/US2020/041837 patent/WO2021007578A1/en not_active Ceased
- 2020-07-13 CA CA3146848A patent/CA3146848A1/en active Pending
- 2020-07-13 KR KR1020227004552A patent/KR20220125210A/ko active Pending
- 2020-07-13 US US17/626,469 patent/US20220288114A1/en active Pending
- 2020-07-13 JP JP2022501111A patent/JP2022541152A/ja active Pending
- 2020-07-13 AU AU2020311441A patent/AU2020311441B2/en active Active
-
2026
- 2026-03-04 AU AU2026201640A patent/AU2026201640A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3146848A1 (en) | 2021-01-14 |
| CN114364355A (zh) | 2022-04-15 |
| AU2020311441B2 (en) | 2025-12-04 |
| US20220288114A1 (en) | 2022-09-15 |
| AU2026201640A1 (en) | 2026-03-26 |
| WO2021007578A1 (en) | 2021-01-14 |
| EP3996644A1 (en) | 2022-05-18 |
| AU2020311441A1 (en) | 2022-02-03 |
| EP3996644A4 (en) | 2023-07-26 |
| JP2022541152A (ja) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023202236B2 (en) | Cross-linking agents and associated methods | |
| US12544400B2 (en) | Treatment of myopic progression | |
| AU2026201640A1 (en) | Multi-agent ocular formulations and treatment methods | |
| US20240122974A1 (en) | Treatment of myopia | |
| HK40107891A (en) | Cross-linking agents and associated methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |